News Sentiment

SCYX sentiment intelligence

Scynexis Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 50 Balanced news tone 43 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Drug Manufacturers - Specialty & Generic Read-through group
Latest close 4.38 Week of 10 Jul 2026
Weighted tone 50/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

83/100 classification confidence.

Company focus 43

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-1.1% over one week, +3.5% over four weeks, trend inactive, and below fair value.

Latest direct headline Negative

FEDERATED HERMES, INC. Acquires 55,207 Shares of SCYNEXIS Inc

Market Reaction

Balanced read

59/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 83/100 classification
One-week reaction -1.1% Price digesting
Trend fit Trend inactive 3.5% over four weeks
Fair value -59.7% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 3
Neutral 35
Negative 5

Relevance

Why the article matched

Direct first
Direct company coverage 43
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
TradingView 11
Stock Titan 7
TradingKey 5
Investing.com 4
GlobeNewswire 3
GuruFocus 2
Investing.com Nigeria 2
Quiver Quantitative 2

Event Lens

What the news is about

Classified themes
Market update 29
Earnings 7
Deals and strategy 2
Regulatory and legal 2
Balance sheet 2
Analyst action 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 43
GuruFocus Direct company coverage

FEDERATED HERMES, INC. Acquires 55,207 Shares of SCYNEXIS Inc

FEDERATED HERMES, INC. recently acquired 55,207 shares of SCYNEXIS Inc for $4.07 per share, a move that now accounts for 4.45% of its portfolio. SCYNEXIS Inc, a drug development company focusing on anti-infectives, has a market cap of $48.958 million, but its financial metrics an

Tone
Negative 41/100
Event
Market update
Published
15 Jul 2026 10:12
Source
GuruFocus
Stock Titan Direct company coverage

Federated Hermes (SCYX) files 13G/A showing 55,207 shares (4.45%)

Federated Hermes, Inc. and related entities have filed an amended Schedule 13G/A, disclosing a passive stake of 55,207 shares in SCYNEXIS (SCYX), which represents 4.45% of the common stock. This filing indicates a passive investment intent and includes a Rule 13d-4 disclaimer, st

Tone
Neutral 50/100
Event
Deals and strategy
Published
08 Jul 2026 12:11
Source
Stock Titan
TradingView Direct company coverage

Enterprise value to EBIT forward of SCYNEXIS, Inc. – NASDAQ:SCYX

This page from TradingView provides financial information for SCYNEXIS, Inc. (NASDAQ: SCYX), specifically focusing on its enterprise value to EBIT forward. It displays the company's financials under the Pharmaceuticals: Major category in the US stock market, indicating it's a dat

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 20:41
Source
TradingView
TMX Newsfile Direct company coverage

Scynexis Deadline Alert

Faruqi & Faruqi, LLP is investigating potential claims against SCYNEXIS, Inc. (NASDAQ: SCYX) and reminds investors of the January 8, 2024 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit. The lawsuit alleges that Scynexis made false or misl

Tone
Negative 18/100
Event
Regulatory and legal
Published
06 Jul 2026 18:41
Source
TMX Newsfile
TradingView Direct company coverage

Enterprise value to EBIT forward of SCYNEXIS, Inc. – FWB:135

The article provides a title for financial data on SCYNEXIS, Inc. (FWB:135) concerning its Enterprise Value to EBIT forward metric. The content indicates that this information would be found under the Financials section of the company's profile on TradingView. However, the specif

Tone
Neutral 50/100
Event
Market update
Published
05 Jul 2026 19:11
Source
TradingView
Sahm Direct company coverage

SCYNEXIS (NASDAQ:SCYX) Is In A Strong Position To Grow Its Business

SCYNEXIS (SCYX) is assessed to be in a strong financial position due to a low cash burn rate and significant revenue growth. The company has a long cash runway of many years, with its cash burn down 78% and operating revenue up 674% over the last year. Analysts believe SCYNEXIS c

Tone
Positive 76/100
Event
Balance sheet
Published
03 Jul 2026 07:11
Source
Sahm
Investing.com Nigeria Direct company coverage

Form DEF 14A Scynexis Inc For: 2 July By Investing.com

This article announces the filing of Form DEF 14A by Scynexis Inc. on July 2nd. It's a brief financial news update from Investing.com, noting the date of the filing. The article also includes stock market data and other news headlines.

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 21:20
Source
Investing.com Nigeria
Stock Titan Direct company coverage

SCYNEXIS (SCYX) director Armando Anido granted stock units and options

SCYNEXIS Inc. director Armando Anido was granted 2,875 shares of Common Stock as restricted stock units and 2,875 stock options, both at no cost. The options have an exercise price of $3.85 and expire on June 25, 2036. Both the restricted stock units and options vest 100% on the

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 07:10
Source
Stock Titan
Investing.com Nigeria Direct company coverage

Form 4 Scynexis Inc For: 30 June By Investing.com

This article from Investing.com announces the filing of a Form 4 for Scynexis Inc. as of June 30, 2026. Form 4 filings report changes in beneficial ownership of a company's securities by insiders. The article provides the title and links to current market data for various indices

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 06:39
Source
Investing.com Nigeria
Stock Titan Direct company coverage

SCYNEXIS (SCYX) director Ann Hanham receives stock and option grants

SCYNEXIS director Ann Hanham received new equity awards, including 2,875 shares of common stock at no cost and 2,875 stock options with a strike price of $3.85 per share. Both the restricted stock units and stock options will vest in full on the first anniversary of the grant dat

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 05:10
Source
Stock Titan
Stock Titan Direct company coverage

SCYNEXIS (NASDAQ: SCYX) director gets RSU and option awards

SCYNEXIS director Guy Macdonald was granted 2,875 restricted stock units (RSUs) and a stock option for 2,875 shares at an exercise price of $3.85 per share on June 26, 2026. Both awards vest fully on the first anniversary of the grant, contingent on his continued service as a non

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 05:10
Source
Stock Titan
TradingView Direct company coverage

Enterprise value to revenue forward of SCYNEXIS, Inc. – FWB:135

The article "Enterprise value to revenue forward of SCYNEXIS, Inc. – FWB:135" focuses on the financial metric of enterprise value to revenue for SCYNEXIS, Inc., trading on the Frankfurt Stock Exchange under ticker 135. It appears to be a financial data page rather than a detailed

Tone
Neutral 50/100
Event
Earnings
Published
01 Jul 2026 05:10
Source
TradingView
Stock Titan Direct company coverage

SCYNEXIS (SCYX) director receives new stock and option awards

SCYNEXIS director David C. Hastings was granted 2,875 shares of common stock and stock options for 2,875 shares with an exercise price of $3.85 per share. Both awards vest 100% on the first anniversary of the June 26, 2026 grant date, provided he continues as a non-employee direc

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 05:10
Source
Stock Titan
Stock Titan Direct company coverage

SCYNEXIS (SCYX) director receives new RSU and stock option grants

SCYNEXIS director Brian Philippe Tinmouth was granted 2,875 restricted stock units and a stock option for 2,875 shares, both vesting one year from June 26, 2026, provided he continues as a non-employee director. The stock option has an exercise price of $3.85 per share and expire

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 04:10
Source
Stock Titan
The Manila Times Direct company coverage

SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

SCYNEXIS, Inc. has initiated a Phase 1 study for SCY-770, a novel AMPK activator, targeting Autosomal Dominant Polycystic Kidney Disease (ADPKD). This study aims to optimize dosing and pharmacokinetics to support a Phase 2 proof-of-concept study expected in Q4 2026. SCY-770 has s

Tone
Positive 75/100
Event
Market update
Published
30 Jun 2026 12:09
Source
The Manila Times
TradingView Direct company coverage

SCYX Forecast — Price Target — Prediction for 2027

The article provides a forecast for SCYNEXIS, Inc. (SCYX) stock, including analyst price targets and current financial data. It notes that three analysts have provided 1-year price forecasts, with estimates ranging from $24.00 to $44.64. The company's current stock price, market

Tone
Neutral 50/100
Event
Analyst action
Published
30 Jun 2026 10:10
Source
TradingView
TradingView Direct company coverage

Price to sales forward of SCYNEXIS, Inc. – NASDAQ:SCYX

This article provides financial data for SCYNEXIS, Inc. (NASDAQ: SCYX), specifically focusing on its price-to-sales forward metric. It details the stock's status as market closed with no trades and lists various services that provide market and reference data for the company.

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 07:41
Source
TradingView
TradingView Direct company coverage

Price to book forward of SCYNEXIS, Inc. – NASDAQ:SCYX

The article provides a snapshot of SCYNEXIS, Inc. (NASDAQ: SCYX) on TradingView, focusing on its "Price to book forward" metric. It lists various sections available on the platform for the company, including financials, news, and technical analysis, but does not provide specific

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 04:41
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of SCYNEXIS, Inc. – GETTEX:135

This article provides financial information for SCYNEXIS, Inc. (GETTEX:135), specifically focusing on its enterprise value to revenue forward metric. The data is presented within the context of the Gettex exchange and is sourced from various financial data providers.

Tone
Neutral 50/100
Event
Earnings
Published
29 Jun 2026 23:41
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBITDA forward of SCYNEXIS, Inc. – NASDAQ:SCYX

The article displays the enterprise value to EBITDA forward for SCYNEXIS, Inc. (NASDAQ: SCYX) on the TradingView platform. It shows the stock information and indicates that the market is closed with no trades. The article is a snapshot from a financial platform, providing basic s

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 05:40
Source
TradingView
TradingView Direct company coverage

Price to sales forward of SCYNEXIS, Inc. – GETTEX:135

The article focuses on the "Price to sales forward" metric for SCYNEXIS, Inc. (GETTEX:135). It appears to be a financial data point provided by TradingView, detailing a specific period, its value, and percentage change. The content itself seems to be a placeholder for financial d

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 01:39
Source
TradingView
Stock Titan Direct company coverage

SCYNEXIS (SCYX) expands authorized stock and registers 87M shares for resale

SCYNEXIS, Inc. (SCYX) has increased its authorized stock from 23,750,000 to 65,000,000 shares, with common stock specifically rising from 18,750,000 to 60,000,000 shares, following stockholder approval at its June 25, 2026 annual meeting. The company also registered up to 87,000,

Tone
Neutral 50/100
Event
Regulatory and legal
Published
26 Jun 2026 20:10
Source
Stock Titan
TradingView Direct company coverage

SCYNEXIS, Inc. Actuals & Estimates (NASDAQ:SCYX)

This article provides a comprehensive overview of SCYNEXIS, Inc. (NASDAQ: SCYX), detailing its current stock price, historical performance, analyst forecasts, and financial data. It includes information on market capitalization, volatility, earnings reports, revenue, net income,

Tone
Neutral 50/100
Event
Earnings
Published
24 Jun 2026 10:10
Source
TradingView
TradingKey Direct company coverage

SCYNEXIS Inc (SCYX) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for SCYNEXIS Inc (SCYX), highlighting its current earnings forecast score, analyst ratings, and price targets. It notes an average price target of $4.00 and that analysts generally recommend a "Buy" trend for the stock, based on 3 analys

Tone
Neutral 50/100
Event
Earnings
Published
18 Jun 2026 12:09
Source
TradingKey
TradingKey Direct company coverage

SCYNEXIS Inc (SCYX) Institutional Confidence

This article analyzes the institutional confidence in SCYNEXIS Inc (SCYX), reporting its current institutional shareholding score as 3.00, which ranks 94th out of 157 in the Pharmaceuticals industry. The institutional shareholding proportion is 25.24%, a 22.57% decrease quarter-o

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 10:09
Source
TradingKey
TradingKey Direct company coverage

SCYNEXIS Inc (SCYX) Financial Health: Profitability & Balance Sheet Analysis

SCYNEXIS Inc (SCYX) has a strong financial score of 9.27, ranking 5th in the Pharmaceuticals industry, indicating robust financial health and high operating efficiency. Despite this, its latest quarterly revenue saw a 100% year-over-year decrease, and net profit fell by 295.08%.

Tone
Negative 39/100
Event
Earnings
Published
18 Jun 2026 10:09
Source
TradingKey
TradingKey Direct company coverage

SCYNEXIS Inc (SCYX) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of SCYNEXIS Inc (SCYX), detailing its current stock price momentum, support and resistance levels, and insights from various technical indicators and moving averages. While the stock is currently trading within a range, technical signals

Tone
Positive 64/100
Event
Market update
Published
18 Jun 2026 09:40
Source
TradingKey
TradingKey Direct company coverage

SCYNEXIS Inc (SCYX) Valuation: PE, PB & Fair Value Analysis

SCYNEXIS Inc (SCYX) currently holds a valuation score of 9.33, ranking 32nd out of 157 companies in the Pharmaceuticals industry. The company's P/E ratio is -7.89, which is significantly below its recent high but above its recent low. Key valuation metrics such as P/B, P/S, and P

Tone
Negative 40/100
Event
Market update
Published
18 Jun 2026 09:40
Source
TradingKey